← Back to Search

Angiogenesis Inhibitor

ChemoID assay for Ovarian Cancer (ACSCO Trial)

Phase 3
Waitlist Available
Led By Kelly J Wilkinson, MD
Research Sponsored by Cordgenics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

ACSCO Trial Summary

This trial will study whether a certain type of cancer cell testing can predict how well a person with ovarian cancer will respond to chemotherapy.

Eligible Conditions
  • Recurrent Ovarian Cancer

ACSCO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression free survival (PFS)
Secondary outcome measures
HRQOL
Median Overall Survival (OS)
Objective Tumor Response

ACSCO Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ChemoID-guided treatmentExperimental Treatment2 Interventions
Participants will be treated with Bevacizumab plus ChemoID-guided standard-of-care chemotherapy drugs from the provided list. ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations: Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will receive the ChemoID assay results from the ChemoID lab.
Group II: Physician Choice treatmentActive Control2 Interventions
Participants will be treated with control chemotherapy treatment (Bevacizumab plus standard-of-care chemotherapy chosen by the Physician from the provided list). Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ChemoID assay
2018
Completed Phase 3
~80
Chemotherapy
2003
Completed Phase 4
~3050

Find a Location

Who is running the clinical trial?

Cordgenics, LLCLead Sponsor
2 Previous Clinical Trials
228 Total Patients Enrolled
Kelly J Wilkinson, MDPrincipal InvestigatorUniversity of Mississippi Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the regulatory standing of ChemoID assay?

"ChemoID assay is believed to be safe based on the available data from Phase 3 clinical trials."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer
2018. "Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03632798.
~13 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top